These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 19263014

  • 1. Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial.
    Bago J, Pevec B, Tomić M, Marusić M, Bakula V, Bago P.
    Wien Klin Wochenschr; 2009; 121(1-2):47-52. PubMed ID: 19263014
    [Abstract] [Full Text] [Related]

  • 2. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.
    Li Y, Huang X, Yao L, Shi R, Zhang G.
    Wien Klin Wochenschr; 2010 Jul; 122(13-14):413-22. PubMed ID: 20628905
    [Abstract] [Full Text] [Related]

  • 3. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial.
    Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J.
    Am J Gastroenterol; 2003 Mar; 98(3):562-7. PubMed ID: 12650788
    [Abstract] [Full Text] [Related]

  • 4. Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.
    Kim MS, Kim N, Kim SE, Jo HJ, Shin CM, Park YS, Lee DH.
    BMC Gastroenterol; 2013 Sep 19; 13():138. PubMed ID: 24050512
    [Abstract] [Full Text] [Related]

  • 5. Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori.
    Ciccaglione AF, Cellini L, Grossi L, Marzio L.
    World J Gastroenterol; 2012 Aug 28; 18(32):4386-90. PubMed ID: 22969203
    [Abstract] [Full Text] [Related]

  • 6. Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy.
    Kang JM, Kim N, Lee DH, Park YS, Kim YR, Kim JS, Jung HC, Song IS.
    Helicobacter; 2007 Dec 28; 12(6):623-8. PubMed ID: 18001404
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection.
    Cheon JH, Kim N, Lee DH, Kim JM, Kim JS, Jung HC, Song IS.
    Helicobacter; 2006 Feb 28; 11(1):46-51. PubMed ID: 16423089
    [Abstract] [Full Text] [Related]

  • 8. Bismuth-based quadruple therapy modified with moxifloxacin for Helicobacter pylori eradication.
    Marušić M, Dominković L, Majstorović Barać K, Gulić S, Bago J, Pezerović D.
    Minerva Gastroenterol Dietol; 2017 Jun 28; 63(2):80-84. PubMed ID: 27973462
    [Abstract] [Full Text] [Related]

  • 9. The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea.
    Chung KH, Lee DH, Jin E, Cho Y, Seo JY, Kim N, Jeong SH, Kim JW, Hwang JH, Shin CM.
    Gut Liver; 2014 Nov 28; 8(6):605-11. PubMed ID: 25368747
    [Abstract] [Full Text] [Related]

  • 10. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
    Uygun A, Kadayifci A, Yesilova Z, Safali M, Ilgan S, Karaeren N.
    Clin Ther; 2008 Mar 28; 30(3):528-34. PubMed ID: 18405790
    [Abstract] [Full Text] [Related]

  • 11. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
    Lim JH, Lee DH, Lee ST, Kim N, Park YS, Shin CM, Song IS.
    World J Gastroenterol; 2015 Dec 14; 21(46):13124-31. PubMed ID: 26673999
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
    Park KN, Hahm JS, Kim HJ.
    Eur J Gastroenterol Hepatol; 1994 Dec 14; 6 Suppl 1():S103-7. PubMed ID: 7735924
    [Abstract] [Full Text] [Related]

  • 13. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection.
    Bang CS, Lim H, Jeong HM, Shin WG, Choi JH, Soh JS, Kang HS, Yang YJ, Hong JT, Shin SP, Suk KT, Lee JJ, Baik GH, Kim DJ.
    Gut Microbes; 2020 Sep 02; 11(5):1314-1323. PubMed ID: 32362221
    [Abstract] [Full Text] [Related]

  • 14. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
    Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F, Pylera Study Group.
    Lancet; 2011 Mar 12; 377(9769):905-13. PubMed ID: 21345487
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication.
    Kim JY, Lee SY, Kim JH, Sung IK, Park HS.
    Helicobacter; 2020 Apr 12; 25(2):e12683. PubMed ID: 32074663
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection.
    Lee ST, Lee DH, Lim JH, Kim N, Park YS, Shin CM, Jo HJ, Song IS.
    Gut Liver; 2015 Jul 12; 9(4):478-85. PubMed ID: 25071068
    [Abstract] [Full Text] [Related]

  • 17. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, Chen MJ, Chen CC, Tseng CH, Hsu YC, Lee JY, Yang TH, Luo JC, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hu WH, Chen YN, Sheu BS, Lin JT, Wu JY, El-Omar EM, Wu MS, Taiwan Gastrointestinal Disease and Helicobacter Consortium.
    Lancet; 2016 Nov 12; 388(10058):2355-2365. PubMed ID: 27769562
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.
    Boixeda D, Bermejo F, Martín-De-Argila C, López-Sanromán A, Defarges V, Hernández-Ranz F, Milicua JM, García-Plaza A.
    Aliment Pharmacol Ther; 2002 Aug 12; 16(8):1457-60. PubMed ID: 12182745
    [Abstract] [Full Text] [Related]

  • 19. Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.
    Kung NN, Sung JJ, Yuen NW, Ng PW, Wong KC, Chung EC, Lim BH, Choi CH, Li TH, Ma HC, Kwok SP.
    Am J Gastroenterol; 1997 Mar 12; 92(3):438-41. PubMed ID: 9068464
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.
    Salmanroghani H, Mirvakili M, Baghbanian M, Salmanroghani R, Sanati G, Yazdian P.
    PLoS One; 2018 Mar 12; 13(6):e0197096. PubMed ID: 29889843
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.